Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00217477 · ClinicalTrials.gov registry record · Phase 1
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00217477 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 34 participants.
The verdict
NCT00217477, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving paricalcitol together with gemcitabine may be an effective treatment for cancer. PURPOSE: This phase I trial is studying the side effects and best dose of paricalcitol when given together with gemcitabine in treating patients with advanced cancer.
Interventions
- DRUG gemcitabine hydrochloride
- DRUG paricalcitol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2004-08 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00217477
The ClinicalTrials.gov registry entry for NCT00217477 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00217477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00217477 about?
NCT00217477 is a clinical study titled "Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer". RATIONALE: Paricalcitol may cause cancer cells to look more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving parical...
What is the current status of trial NCT00217477?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2004-08. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00217477?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), paricalcitol (DRUG).
Who is sponsoring clinical trial NCT00217477?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.